🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a single center Phase I clinical trial of FT516 administered intrap...
Status
Completed
Location
University of Minnesota, Masonic Cancer Center
Start Date
2021-04-02
Trial ID
NCT04630769
Treatments Being Tested
This study evaluates the safety, anti-tumor effect, and immunogenicity of E...
Status
Active Not Recruiting
Location
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Start Date
2017-02-14
Trial ID
NCT02923180
Treatments Being Tested
The purpose of this study is to evaluate the safety of enoblituzumab (MGA27...
Status
Completed
Location
Mayo Clinic - AZ
Start Date
2015-07
Trial ID
NCT02475213
Treatments Being Tested
This is an open-label study designed to evaluate safety and efficacy of eno...
Status
Withdrawn
Location
Multiple Locations
Start Date
2019-10
Trial ID
NCT04129320
Treatments Being Tested
This is a Phase 2 study of enoblituzumab combined with either retifanlimab ...
Status
Terminated
Location
University of Maryland, Greenebaum Comprehensive Cancer Center
Start Date
2021-03-17
Trial ID
NCT04634825
Treatments Being Tested
The purpose of this study is to evaluate the safety of enoblituzumab (MGA27...
Status
Completed
Location
UCLA Hematology-Oncology Clinic
Start Date
2015-03-26
Trial ID
NCT02381314
Treatments Being Tested
This study is a Phase 1, open-label, dose escalation and cohort expansion t...
Status
Completed
Location
Lucile Packard Children's Hospital, Stanford
Start Date
2016-12
Trial ID
NCT02982941
Treatments Being Tested
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of...
Status
Active Not Recruiting
Location
Northewestern University
Start Date
2024-02-16
Trial ID
NCT06014255
Treatments Being Tested
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when adm...
Status
Terminated
Location
Masonic Cancer Center - University of Minnesota
Start Date
2023-04-28
Trial ID
NCT05708924
Treatments Being Tested